Novocure (NVCR) Tops Q3 EPS by 7c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. META
5. TSLA
6. ISRG
7. SMCI
8. RTX
9. S
10. COF

Go back to Novocure (NVCR) Tops Q3 EPS by 7c

Novocure Reports Third Quarter 2023 Financial Results

October 26, 2023 7:00 AM EDT

Quarterly net revenues of $127 million with 3,639 active patients on therapy as of September 30, 2023

ROOT, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended September 30, 2023. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields).

We are focused on extending survival in some of the most aggressive forms of cancer, said Asaf Danziger, Novocures Chief Executive Officer. This quarter we continued our very successful launch in... More